Gauvreau, Gail M and Arm, Jonathan P and Boulet, Louis-Philippe and Leigh, Richard and Cockcroft, Donald W and Davis, Beth E and Mayers, Irvin and FitzGerald, J Mark and Dahlen, Barbro and Killian, Kieran J and Laviolette, Michel and Carlsten, Christopher and Lazarinis, Nikolaos and Watson, Richard M and Milot, Joanne and Swystun, Veronica and Bowen, Miranda and Hui, Linda and Lantz, Ann-Sofie and Meiser, Karin and Maahs, Suzanne and Lowe, Philip J and Skerjanec, Andrej and Drollmann, Anton and O'Byrne, Paul M (2016) Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. The Journal of allergy and clinical immunology, in pre (in pre). 00-00. ISSN 1097-6825

Abstract

Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab.

Item Type:	Article
Date Deposited:	16 Sep 2016 00:45
Last Modified:	16 Sep 2016 00:45
URI:	https://oak.novartis.com/id/eprint/30938